Welcome to our dedicated page for Hinge Health SEC filings (Ticker: HNGE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Hinge Health, Inc.'s SEC filings document its public-company reporting as an emerging growth company operating a technology platform for musculoskeletal care. Its Form 8-K filings cover quarterly and annual financial results, furnished earnings releases, supplemental investor materials, non-GAAP financial measures and reconciliations, and Regulation FD disclosures.
The company’s filings also record governance and capital-structure matters, including proxy materials for director elections and auditor ratification, board appointments and committee assignments, share repurchase authorization, Class A common stock disclosures, and post-IPO lock-up matters. These documents provide formal disclosure on operating results, stockholder voting matters, board oversight, capital allocation and securities-related events.
Hinge Health, Inc. Chief Financial Officer James Budge reported open-market sales of a total of 5,907 shares of the company’s Class A Common Stock on May 26, 2026. The transactions were executed under a pre-arranged Rule 10b5-1 trading plan.
The sales occurred in three tranches: 3,507 shares at a weighted average price of $53.3237, 2,100 shares at $54.3733, and 300 shares at $55.2233. All reported holdings are direct, and no option exercises or derivative transactions are included in this filing.
Hinge Health, Inc. president James Pursley reported selling a total of 16,000 shares of Class A Common Stock in open-market transactions. The sales occurred on May 26, 2026 at weighted average prices of about $53–$55 per share, with individual trades recorded at $53.29, $54.29 and $55.16.
After these transactions, Pursley directly holds 780,223 shares. A footnote explains that at least one line of sales was effected under a Rule 10b5-1 trading plan adopted on June 13, 2025, and that his holdings include 781 shares acquired on May 15, 2026 through the company’s employee stock purchase plan.
Hinge Health director and Executive Chairman Gabriel Mecklenburg reported a planned mix of sales and conversions of Hinge Health, Inc. stock. On May 26, 2026, he sold a total of 83,333 shares of Class A Common Stock in open-market transactions at weighted average prices in the mid‑$50 range under a pre‑arranged Rule 10b5‑1 trading plan adopted on December 1, 2025. These sales were paired with the conversion of 83,333 shares of Class B Common Stock into Class A Common Stock. After these transactions, he continues to hold a substantial stake through 1,860,675 shares of Class B Common Stock directly, plus additional Class B holdings equivalent to 383,592 and 857,880 underlying Class A shares through a family trust and a GRAT, respectively, as well as 944,250 performance stock units that are noted but excluded from the share totals.
James Budge reported Rule 144 resale notices for sales executed under a 10b5-1 plan. The excerpt lists three completed sales: 11,006 shares on 03/23/2026 for $465,138.87, 5,906 shares on 05/11/2026 for $323,758.65, and 781 shares on 05/20/2026 for $43,220.54. It also lists 5,907 Restricted Stock Units dated 05/01/2026 as securities to be sold. Brokerage information names Morgan Stanley Smith Barney LLC.
HNGE filing reports a broker notice of proposed resale of 82,000 Performance Stock Units and records a 10b5-1 market sale by James Pursley of 15,000 common shares on 03/23/2026 for $633,927. The filing lists a reference figure of 54,655,926 (dated 05/26/2026) as a context number.
Hinge Health, Inc. Chief Financial Officer James Budge sold 781 shares of Class A Common Stock in an open-market transaction at $55.34 per share on May 20, 2026. After this sale, he directly holds 451,293 shares. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan, and his holdings include shares issued through the company’s employee stock purchase plan.
HNGE proposed sale of 781 shares of Common Stock. The Form 144 lists 781 shares to be sold pursuant to an Employee Stock Purchase Plan on 05/15/2026 for cash through Morgan Stanley Smith Barney LLC. The filing also discloses recent 10b5-1 sales by James Budge on 02/23/2026 (14,763 shares, $580,736.79), 03/23/2026 (11,006 shares, $465,138.87), and 05/11/2026 (5,906 shares, $323,758.65).
Hinge Health, Inc. President James Pursley received a grant of 65,000 shares of Class A Common Stock on April 29, 2026 through a restricted stock unit (RSU) award. The RSUs were granted for no cash consideration and each RSU converts into one share upon vesting. Following this award, Pursley directly holds 795,442 shares of Class A Common Stock reported in this filing.
Hinge Health, Inc. reported that Chief Financial Officer James Budge received an award of 65,000 shares of Class A Common Stock in the form of restricted stock units. The RSU grant was acquired for no cash consideration and brings his directly held stake to 451,293 shares.
Hinge Health, Inc. Chief Financial Officer James Budge sold 5,906 shares of Class A Common Stock in open-market transactions. The sales occurred on May 11, 2026 at weighted average prices of $55.48 and $54.65 per share under a pre-arranged Rule 10b5-1 trading plan. Following these transactions, he continued to hold 386,293 shares directly, indicating that the trades represent a small portion of his overall stake.